IHAT 02
Alternative Names: IDAX; IHAT-02Latest Information Update: 16 Sep 2021
At a glance
- Originator Nemysis
- Class Antianaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Anaemia
Most Recent Events
- 26 Aug 2021 IHAT 02 is available for licensing as of 26 Aug 2021. https://nemysisltd.com/ (Nemysis website, August 2021)
- 26 Aug 2021 Phase-II clinical trials in Anaemia in Ireland (PO) (Nemysis pipeline, August 2021)
- 26 Aug 2021 Preclinical trials in Anaemia in Ireland (PO), prior to August 2021 (Nemysis pipeline, August 2021)